Next-Gen Nanobodies With MoonLake's Jorge Santos Da Silva, Ph.D.
Business Of Biotech
00:00
The Benefits of Nanobody Therapy for Psoriasis
We know from all the binding evidence that we have that we are an extremely strong binder to both the cytokines, not just A, which is what cosantics targets. We will now see more data from B-mikizumab in March. The UCP product, the only other product that any of it say in F in HS. And then in June, we will come out, Matt, and we will turn the card. And we will say, these guys went for 75% improvement. Do they meet the primary endpoint or not?
Transcript
Play full episode
